Boehringer Biosimilar Flouts 74 Patents, AbbVie Says
Boehringer Ingelheim's proposed biosimilar of the immunosuppressant Humira runs afoul of 74 patents that shield the mega-blockbuster from competition, AbbVie said in a complaint filed Wednesday in Delaware federal court....To view the full article, register now.
Already a subscriber? Click here to view full article